Expression of histone deacetylases and acetyltransferases in HIV-1 infected monocytederived macrophages

Ariel Burns, Pawel Olszowy and Pawel Ciborowski

: J Antivir Antiretrovir

Abstract :

A pproximately 15-30% of breast cancers over-express the HER2/neu receptor. Historically, over-expression of HER2/neu has been identified using IHC or FISH, both of which are invasive approaches requiring tissue samples. Patients with positive IHC/FISH tests can have the option of receiving HER2/neu targeted treatment. However, recent evidence has shown that some tumors identified as ?negative? using these methods also respond to HER2/neu targeted therapy. Shedding of the extracellular domain (ECD) of the receptor into the circulation has led to the development of serum test of HER2 ECD as an additional approach to probe HER2/neu overexpression. Yet more than 10 years after the first serum HER2 ECD test was approved by the FDA, serum HER2 testing has yet to be widely used in clinical practice. We have developed an assay to reduce serum interference that commonly occurs in practice and discourages the use of ELISA type of assay. Using this refined assay, we are able to accurately correlate serum HER2 ECD levels with tissue HER2/neu status. With this test, we can monitor HER2 ECD as a biomarker over the course of disease progression and treatment. It will also help screen patients who have no available tissue samples for HER2/ neu targeted therapies